• 제목/요약/키워드: 재발성 다형선종

검색결과 2건 처리시간 0.015초

일차성 폐의 침샘형 악성 다형선종 (Primary Pulmonary Carcinoma Ex-pleomorphic Adenoma of the Salivary Gland Type)

  • 박상준;조성우;이희성
    • Journal of Chest Surgery
    • /
    • 제43권2호
    • /
    • pp.217-220
    • /
    • 2010
  • 소위 다형선종이라 불리는 혼합종은 주로 침샘에 기원하며 폐에서 발생한 예는 세계적으로 보고된 예가 극히 드물다. 이 신생물은 저악성도를 나타내기도 하나 재발이나 원격전이와 같은 공격적인 성향을 보이는 경우도 있다. 우리는 종양의 완전 절제후 병리학적으로 폐의 일차성 악성 다형선종임을 확인하였고 술 후 다발성 전이와 같은 악성 신생물의 소견을 보이는 증례를 경험하여 이를 보고하는 바이다.

원발성 다형선종과 재발성 다형선종의 면역조직화학적 특성 (Immunohistochemical Characteristics of Primary and Recurrent Pleomorphic Adenoma)

  • 서명환;하정훈;이경분;정영호;권성근;김광현;성명훈
    • 대한두경부종양학회지
    • /
    • 제21권2호
    • /
    • pp.146-150
    • /
    • 2005
  • Background and Objectives: When the pleomorphic adenoma(PA) recures, the tumor tends to become a multinodular mass that infiltrates into the normal tissue which is not a common condition for a benign tumor. This manifestation is probably due to the difference in cell biology of the recurrent tumor compared to that of the primary PA. The aim of this study is to assay the immunhistochemical characteristics of the recurrent PA compared to the primary PA and to evaluate whether this property can be used for developing a method that can select the patients who have higher risk to recur. Materials and Methods: Thirteen patients were enrolled in the primary PA group and 15 patients who had a recurrent PA were enrolled in the recurrent PA group. To evaluate the cell biology of the tumor, immunohistochemical stainings of Ki-67, bcl-2 and p53 were performed. Results: There was no difference in the expression of Ki-67 (p=0.117, p=.208) and p53 (p=.430, p=.328). The extent stained by bcl-2 was significantly larger in the recurrent PA group (p=.033, p=.014). The expression of bcl-2 did not increase while time passed. Conclusion: The high expression of bcl-2 seems to be a property of the recurrent PA group which can be found even during first operation before recurrence. By this immunhistochemical characteristic, we would be able to sort out the patients who have higher risk to recur.